- Home
- STRW vs UNCY Comparison
STRW vs UNCY Comparison
Compare STRW & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STRW | UNCY |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.1M | 126.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | STRW | UNCY |
|---|---|---|
| Price | $13.26 | $6.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $12.72 | ★ $44.50 |
| AVG Volume (30 Days) | 28.6K | ★ 394.0K |
| Earning Date | 02-26-2026 | 11-12-2025 |
| Dividend Yield | ★ 4.79% | N/A |
| EPS Growth | ★ 19.41 | N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $145,392,000.00 | N/A |
| Revenue This Year | $35.42 | N/A |
| Revenue Next Year | $7.19 | N/A |
| P/E Ratio | $21.97 | ★ N/A |
| Revenue Growth | ★ 29.76 | N/A |
| 52 Week Low | $8.70 | $3.71 |
| 52 Week High | $14.00 | $11.00 |
Technical Indicators
Market Signals| Indicator | STRW | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 56.36 | 57.43 |
| Support Level | $13.18 | $5.65 |
| Resistance Level | $13.56 | $5.95 |
| Average True Range (ATR) | 0.29 | 0.40 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 72.25 | 87.38 |
Price Performance
Historical ComparisonAbout STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.